Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma

Elisabetta Cenni, Francesca Perut, Donatella Granchi, Sofia Avnet, Ilaria Amato, Maria Luisa Brandi, Armando Giunti, Nicola Baldini

Research output: Contribution to journalArticlepeer-review


Background: Fibroblast growth factor-2 (FGF-2) has a role in the angiogenesis induced by renal carcinoma. Materials and Methods: Blockage of FGF-2 by an antisense oligonucleotide (ASO) or by a mouse neutralizing anti-human FGF-2 monoclonal antibody (anti-FGF-2-mAb) was evaluated on a cell line isolated from a renal carcinoma bone metastasis (CRBM-1990), on Caki-1 and ACHN cells. Cocultures of endothelial cells and ASO- or mAb-treated carcinoma lines were investigated. Results: Anti-FGF-2-mAb treatment induced a 33% reduction of FGF-2 released by ACHN, a 31% reduction of FGF-2 released by Caki-1, and a 70% reduction of FGF-2 released by CRBM-1990. ASO treatment did not inhibit endothelial cell proliferation. In contrast, anti-FGF-2-mAb significantly decreased endothelial cells proliferation induced by ACHN and CRBM-1990. The inhibition of endothelial cell growth was reverted by recombinant FGF-2. Conclusion: Modulation of FGF-2 production by renal cell carcinoma with a blocking mAb produced a significant inhibition of endothelial cell growth.

Original languageEnglish
Pages (from-to)315-320
Number of pages6
JournalAnticancer Research
Issue number1 A
Publication statusPublished - Jan 2007


  • Angiogenesis
  • Antisense oligodeoxynucleotide
  • Bone metastasis
  • Fibroblast growth factor-2
  • Neutralizing antibody
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this